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Abstract
Background: The recurrence and non-random distribution of translocation breakpoints in human tumors are usually
attributed to local sequence features present in the vicinity of the breakpoints. However, it has also been suggested that
functional constraints might contribute to delimit the position of translocation breakpoints within the genes involved, but a
quantitative analysis of such contribution has been lacking.
Methodology: We have analyzed two well-known signatures of functional selection, such as reading-frame compatibility
and non-random combinations of protein domains, on an extensive dataset of fusion proteins resulting from chromosomal
translocations in cancer.
Conclusions: Our data provide strong experimental support for the concept that the position of translocation breakpoints
in the genome of cancer cells is determined, to a large extent, by the need to combine certain protein domains and to keep
an intact reading frame in fusion transcripts. Additionally, the information that we have assembled affords a global view of
the oncogenic mechanisms and domain architectures that are used by fusion proteins. This can be used to assess the
functional impact of novel chromosomal translocations and to predict the position of breakpoints in the genes involved.
Citation: Ortiz de Mendı´bil I, Vizmanos JL, Novo FJ (2009) Signatures of Selection in Fusion Transcripts Resulting From Chromosomal Translocations in Human
Cancer. PLoS ONE 4(3): e4805. doi:10.1371/journal.pone.0004805
Editor: Michael J. Pazin, National Institute on Aging (NIA), National Institutes of Health (NIH), United States of America
Received October 8, 2008; Accepted January 30, 2009; Published March 12, 2009
Copyright:  2009 Ortiz de Mendı´bil et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work has been funded with the help of the Institute of Health Carlos III (FIS PI040037), Spanish Ministry of Education and Science (SAF 2007-62473),
the PIUNA Program of the University of Navarra and the Caja Navarra Foundation through the Program ‘‘You choose, you decide’’ (Project 10.830). F.J.N is the
recipient of a ‘‘Jero´nimo de Ayanz’’ award from the Government of Navarra. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: fnovo@unav.es
Introduction
Most cancer cells display some type of chromosomal rearrange-
ment. Whereas solid tumors usually display complex karyotypes
with many different types of chromosomal rearrangements, many
hematological malignancies and certain sarcomas display only one
or a few aberrations, usually balanced chromosomal transloca-
tions, which in some cases have been shown to be the initiating
event in tumor development [1,2]. For this reason, chromosomal
translocations are technically easier to characterize in hematolog-
ical cancers. Extensive analysis of chromosomal translocations in
human malignancies over the past three decades has revealed two
main outcomes by which such rearrangements drive cancer
progression: i) promoter exchange (mainly in lymphoid neo-
plasms), and ii) creation of chimeric genes that are translated as
fusion proteins (myeloid leukemias and some solid tumors) [3].
Likewise, the consensus derived from these studies suggests that
chromosomal translocations are the result of misrepaired DNA
double-strand breaks (DSB) in somatic cells [4–7]. Chromosomal
translocations resulting in chimeric fusion transcripts constitute an
important group of reciprocal translocations that accounts for 20%
of cancer morbidity in humans [3], and have the potential to
initiate tumor growth because their protein products contain
domains from both fusion partners. The presence of heterologous
protein domains in the same chimeric protein results in
deregulated biological activities that ultimately lead to cancer
development.
Some of the balanced chromosomal translocations found in
tumors are recurrent, in the sense that they are present in different
patients with the same tumor type, or even in different tumor types
[8]. Furthermore, characterization of fusion sequences at the
molecular level in different patient samples has shown that, at least
for a few genes, breakpoints tend to cluster in specific regions. As a
result, the distribution of translocation breakpoints found in tumor
samples follows a non-random pattern, with a few sites in which
breakpoints are more frequent than expected by chance. Although
several studies have addressed the potential role of nucleotide
motifs and local sequence features as the cause for such recurrence
[9–14], the importance of functional factors in delimiting the
position of translocation breakpoints has not been tested
experimentally. In this regard, a global analysis of chimeric fusion
transcripts could show whether breakpoint recurrence might be
the result of cellular selection for the functions encoded by specific
domains that are present in the respective fusion proteins.
Furthermore, the requirement to keep an intact reading frame
in the fusion product could also contribute to explain the non-
random distribution of translocation breakpoints across those
genes.
In order to test this hypothesis, we have analyzed a
comprehensive set of chromosomal translocations that create
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oncogenic fusion proteins in human malignancies, looking for
signatures of functional selection. We compiled a catalogue of the
protein domains encoded by those fusion proteins and visualized
them as a network of interacting nodes, obtaining a global view of
the protein domains that are brought together to the same fusion
proteins. We also analyzed the reading frame of the fusion
transcripts, in order to confirm that the original reading frames of
the partner genes were kept in-frame in fusion transcripts in a
proportion higher than expected by chance.
Materials and Methods
Fusion sequences were obtained from TICdb version 2.1
(October 2007). TICdb is a freely available database of gene-
mapped translocation breakpoints in cancer, which describes the
genomic location of 1,445 translocation breakpoints, correspond-
ing to 310 different genes, in hematological, mesenchymal and
epithelial malignancies. The database was created using informa-
tion from the Mitelman Database of Chromosome Aberrations in Cancer
(available at the Cancer Genome Anatomy Project), two published
catalogs of genes rearranged in cancer and our own searches [15].
Junction sequences of reciprocal translocations were mapped onto
the reference sequence of the human genome using BLAST. All
translocation breakpoints are thus referred to precise nucleotide
positions or gene fragments (introns or exons) within specific
Ensembl transcripts (Ensembl 38.36).
The procedure followed is summarized in Figure 1. From
TICdb, we obtained information about 699 different oncogenic
gene fusions, excluding from further analysis all those transloca-
tions in which the oncogenic mechanism has been shown to be
gene de-regulation by promoter exchange instead of the creation
of a fusion protein. Likewise, 116 fusions in which at least one of
the partner genes did not contribute a recognizable protein
domain to the fusion protein were uninformative for the analysis of
protein domain co-occurrences, and were thus excluded from the
dataset because they are not eligible for the study. In total, we
analyzed 583 gene fusions in which both partner genes contributed
an annotated protein domain to the chimeric fusion protein
generated by the translocation. Two thirds (66%) of these fusions
were reported in hematological malignancies, 26% in mesenchy-
mal cancers and 8% in epithelial tumors.
TICdb shows the position of each breakpoint mapped to a
particular intron or exon of a specific Ensembl transcript. This
enabled us to use Ensembl ‘‘Protein view’’, which provides a
graphical representation of the protein and of all the domains
annotated in SMART, PFAM, PROSITE and PRINTS databas-
es, in order to extract, for every gene fusion, the PFAM and
PROSITE domains that are contributed to the fusion protein by
each one of the partner genes. When PFAM and PROSITE
domains overlapped and/or had the same INTERPRO accession
number, we considered the PFAM entry only. Unique PROSITE
domains without INTERPRO annotations were ignored; these
include low complexity regions such as proline-rich, serine-rich or
glutamine-rich regions. Coiled coil regions were included in the
analysis, since they are important oligomerization domains used in
many fusion proteins.
An important consideration about protein domains in native
proteins is that many domains are generally found in combination
with other domains in the same protein. This means that fusion
proteins will usually receive two or more domains from each one
of the translocation partners. In these cases, it is difficult to
establish whether only one (and which) of the domains is
responsible for the oncogenic properties of the fusion protein, or
whether it is that particular combination of domains that is
responsible for oncogenic activity. For this reason, we grouped
domains into domain architectures, that is, groups of domains that
are found together in the same native proteins according to Pfam
annotations. Two architectures, EAD and COIL, were particu-
larly difficult to assign. The first includes the EWS activation
domain, which is not annotated as a protein domain in PFAM but
has been shown to be responsible for the transforming potential of
fusion proteins containing this part of the EWS protein.
Interestingly, this domain is also detected, by sequence similarity,
in the FUS and TAF15 proteins, which form fusion proteins with
architectures found in EWS fusions. With respect to the coiled coil
domain, it is present in many proteins but also lacks an annotation
in protein domain databases. It appears in fusion proteins either
alone or in combination with other domains, so it is not always
clear whether the transforming potential of the fusion protein is
due to the oligomerization properties of the coiled coil or to the
combined presence of this domain with other protein domains.
For this reason, we created one architecture (COIL) for those
fusion proteins in which the coiled coil is the only domain present,
plus various other architectures (COIL/other) for those cases in
which other domains are found in combination with coiled coils.
The NUP architecture is comprised by the GLFG repeats of the
NUP protein.
We then generated a list of domain architectures that are
brought together to the same fusion protein. These pairs of
domain architectures were visualized as networks in which nodes
represent a domain architecture, and edges link those architectures
that are present in the same fusion protein. Networks were created
using Cytoscape 2.5 (http://cytoscape.org/). Analysis of network
parameters was performed using the NetworkAnalyzer plugin
[16]. Supplementary Table S1 lists all architectures with the
domains comprising each architecture.
The Ensembl ‘‘Protein view’’ also shows the reading frame in
which every coding exon starts and ends (boxes shown in Figure 1).
Since all translocations in TICdb are mapped to specific introns or
exons, we were able to check whether the exons flanking a
translocation breakpoint have compatible reading frames, that is, if
the last exon of the 59 partner gene ends in the same reading frame
in which the first exon of the 39 partner gene starts. As shown in
Figure 1, this can be used to infer whether the fusion gene resulting
from the translocation would keep the reading frame from both
partner genes, and thus be translated as an in-frame fusion protein.
Since most of the fusion sequences analyzed are derived from
fusion transcripts (spliced mRNAs), these sequences already take
into account potential exon skipping or alternative splicing events.
In 43 of the 583 gene fusions analyzed, the reading frame of both
exons seemed incompatible with an in-frame fusion product, so we
went back to the original sequence to check whether other




Following the strategy explained in Methods, we analyzed
reading frame compatibility of exons flanking translocation
breakpoints, in 583 gene fusions coding for a potential fusion
protein in which with both partner genes contribute an annotated
protein domain. Interestingly, the final reading frame of the 59
exon and the starting reading frame of the 39 exon were
compatible in 540 of the fusions analyzed, thus confirming that
an in-frame fusion protein was generated in 93% of the cases. In
some translocations, the breakpoint fell in the middle of an exon,
but even so the reading frame was kept across the fusion. This is
Fusion Transcript Selection
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illustrated by a set of gene fusions between FIP1L1 (59 gene) and
PDGFRA (39 gene) in which different exons of FIP1L1 are fused to
truncated versions of exon 12 of PDGFRA (Ensembl transcript
ENST00000381354). Deletions in this exon always result in a
compatible reading frame with the corresponding exons of FIP1L1
(exons 10, 11, 12 and 13 of FIP1L1 transcript ENST00000358575,
which end in reading frames +3, +1, +2 and +3 respectively, in
version 38.36 of Ensembl), leading to in-frame fusion transcripts in
all four configurations.
In the remaining 43 fusions the reading frames of flanking
exons were not compatible, so they would not be expected to
generate an in-frame fusion protein. In these cases we went back
to the original fusion sequence and found that in 31 of these
(72%) the reading frame had been restored by various mechanisms
such as alternative splicing, insertion of intronic regions, insertion
of non-templated nucleotides or deletion of exonic nucleotides.
This was particularly common in fusion proteins involving
EWSR1, FUS and TAF15, since 48% of such fusions had
incompatible reading frames that were corrected by one of these
mechanisms (24 out of 50 gene fusions analyzed for these genes).
After careful evaluation of the remaining 12 fusions in which
reading frames were not compatible (2% of the total 583 fusions),
we assumed that a functional protein product cannot be generated
in these cases.
The finding that 98% of gene fusions generate transcripts that
can be translated as in-frame protein products confirms that
reading frame conservation is of great functional importance in
oncogenic fusion proteins, since the expected frequency of
compatible reading frames between two random exons (assuming
equal frequencies of +1, +2 and +3 reading frames) is one third.
This is a clear signature of the strong selective pressure in somatic
cells that favors those fusion products capable of driving oncogenic
transformation, and it has important implications in the discussion
about the identity of the factors that govern the position of
translocation breakpoints in cancer cells (see below).
Protein domain architectures present in the same fusion
protein
A network graph of the genes involved in chromosomal
translocations that generate fusion proteins (Supplementary Figure
S1) shows three main independent clusters, plus some smaller
graphs that are not connected to any of the main components
[15,17]. These were analyzed as explained in the Methods section,
in order to create a global network of domain architectures that
are brought together to the same fusion proteins in cancer (Figure 2
and Supplementary Text S1). Topological parameters such as
degree distribution show that the network of gene fusions and the
network of domain architectures are both compatible with scale-
Figure 1. Procedure for the extraction of the data used in this study. For each fusion in TICdb (top rectangle shows part of the screenshot of
a search for translocations involving ETV6) we went to the ‘‘Protein view’’ page of the respective transcripts (ENST00000266427 and
ENST00000381652 in this example). The bottom left box shows the ETV6 protein with the aminoacids coded by each exon (blocks of alternating
color), the position of protein domains annotated in several databases (SMART, SUPERFAMILY, PFAM, PROSITE and PRINTS), the location of the
breakpoint (vertical dotted line) and the part of the peptide that is contributed to the fusion protein (horizontal line with double arrowhead). The
same is shown for JAK2 in the bottom right box. In both cases, the exon flanking the fusion is highlighted (red rectangle), with its starting and ending
reading frames shown in a box (‘‘Splice information’’).
doi:10.1371/journal.pone.0004805.g001
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free or small-world, but not random, topologies. The number of
nodes (114) in the network of domain architectures (Figure 2) is less
than half the number of genes rearranged in those translocations
(235 nodes in Figure S1), indicating that the same architectures are
used in different gene fusion events. Likewise, the network of
domain architectures has a smaller diameter (8 vs. 13) and a
smaller characteristic path length (3.66 vs. 4.83); as a result,
network density in the network of domain architectures is more
than twice the density of the network of gene fusions (0.0019 vs.
0.0008). These parameters reflect the lower complexity of the
network of domain architectures with respect to the network of
gene fusions. A more in-depth discussion of these networks can be
Figure 2. Global view of protein domain architectures in oncogenic fusion proteins. All domain architectures were merged together,
resulting in a single large component plus 6 other smaller graphs. Nine nodes with more than 5 neighbors (hubs) are shown in blue. The three main
gene fusion networks shown in Supplementary Figure S1 are clearly visible in the hubs corresponding to TK, NUP and COIL/HZ architectures. The size
of each node is indicative of its degree (number of neighbors).
doi:10.1371/journal.pone.0004805.g002
Fusion Transcript Selection
PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e4805
found in Supplementary Text S1, Supplementary Figure S2,
Supplementary Figure S3, Supplementary Figure S4 and Supple-
mentary Figure S5.
Two interesting features are apparent in the network of domain
architectures. First, all the architectures derived from the three
main gene fusion networks appear as a large single graph,
indicating that some domain architectures are common to all gene
networks. Likewise, some of the architectures from the 21 small
gene fusion graphs are also included in this large component, so
that only 6 small components remain unconnected to the main
network of domain architectures. Second, the more connected
nodes (hubs with$5 neighbors, shown in blue in Figure 2) identify
the main classes of fusion proteins found in cancer, that is, those
involving the tyrosine kinase (TK) domain, the EWS activation
domain (EAD), the Runt domain, the ligand binding domain of
the nuclear hormone receptor (HRMN), the AT-hook DNA
binding domain (HOOK and COIL/HZ), the GLFG repeats
(NUP) and coiled coils (COIL). This suggests that the network
captures the main biological themes that are presently known to be
used by fusion proteins in cancer.
The finding that only certain combinations of protein do-
mains are present in oncogenic fusion proteins, forming a net-
work of non-random topology, implies that such combinations
are the result of distinct functional constraints. As mentioned
above, this is a signature of the cellular selection pressures that
dictate which chromosomal translocations are present in cancer
cells.
In order to anticipate how this network will be affected by the
discovery of new translocations, we analyzed chromosomal
translocations that were published after the beginning of this
work (October 2007) and thus not yet included in TICdb at the
time [18–33]. We collected 17 gene fusions that generate a fusion
protein with annotated protein domains, describing 9 new genes
and 7 novel domain architectures (two of the new genes
contributed an already described architecture). We also observed
two novel combinations of previously described domain architec-
tures. Additionally, in one case a 39 partner gene (TCF3),
previously described as 59 fusion partner, contributes a distinct
domain architecture in this new case. The analysis of these new
fusions suggests that the network of domain architectures, even
though not yet complete, contains most of the architectures used
by oncogenic fusion proteins, and grows at a slower rate than the
network of gene fusions.
Discussion
We have performed an unbiased survey of the literature and of
all public data available to us about chromosomal translocations
which create fusion proteins in human cancers. Fusions that were
not informative for this analysis were excluded, namely those
involved in promoter exchange (which do not create fusion
proteins) and those in which one of the partner genes did not
contribute a recognizable domain to the fusion protein (which are
not informative for the analysis of domain co-occurrence).
Therefore, it must be kept in mind that the data presented here
apply to chromosomal translocations which generate fusion
proteins containing protein domains annotated in Pfam. Our
analysis revealed two signatures of functional selection: reading-
frame compatibilty and non-random co-occurrence of protein
domains. Both features might be important determinants of the
position of translocation breakpoints in cancer cells. Additionally,
our data could help to predict new translocations and to assess the
functional relevance of novel gene fusions discovered in hemato-
logical and solid tumors.
Role of functional selection in the position of
translocation breakpoints in cancer cells
The two signatures of functional selection that we have analyzed
in fusion transcripts (namely, reading frame conservation and non-
random combinations of protein domains) suggest that such forces
might be major factors in determining the non-random distribu-
tion of translocation breakpoints that is seen in human cancers. In
this regard, the widely held view that local sequence factors are
responsible for the presence of translocation breakpoints at specific
genomic sites relies on the assumption that translocation break-
points reveal the location of all DSBs generated in those cells.
Thus, since translocation breakpoints are non-randomly distrib-
uted, the inference is made that DSBs are initially created non-
randomly. However, sequence elements responsible for the
generation of DSBs (short sequence motifs, topoisomerase II sites,
dispersed repeats, intronic transcription initiation sites, cruciform
structures, etc) are fairly common throughout the genome, so it is
reasonable to suppose that most of the DSBs that are created
across the genome during the lifetime of a somatic cell have been
properly repaired and that only a small subset of misrepaired
DSBs will result in oncogenic fusions and will eventually be found
in tumor samples. In this respect, it must be kept in mind that the
analysis of tumor samples represents an extreme case of
ascertainment bias: by definition, only translocations that have
been important for tumor growth will be detected, whereas many
other possible translocations that did not provide a proliferative
advantage to the cell will not. Some translocations, for example,
would be expected to be deleterious to the cell, since two different
gene alleles (one allele of each gene) have been inactivated by the
breaks, so that cells carrying those translocations will eventually
disappear from the tissue. Other rearrangements will be
functionally neutral and the resulting fusion gene will not have
an advantageous biological function. In the end, the translocations
that are found in tumor samples are the result of the clonal
expansion of cells that harbor translocations with the potential to
promote tumor growth because they create oncogenic fusion
genes. The specific breakpoints harbored by these translocations
constitute the subset of non-random translocation breakpoints that
are found in cancer cells.
This is illustrated in Figure 3, which shows two genes
theoretically capable of participating in a reciprocal translocation
with oncogenic properties, due to the domains that are present in
their respective proteins. Even if the initial DSBs were distributed
uniformly across those genes [34], it is obvious that not all possible
translocations will create a fusion gene with oncogenic potential.
Looking at the position of the regions that code for the necessary
protein domains, and considering the reading frames of the
various exons involved, it becomes clear that an oncogenic fusion
protein will only be generated if breakpoints are located within
certain introns. Other possible breakpoint combinations would
lead to the loss of an important functional domain in the fusion
protein, or to an out-of-frame product, and will not be favoured in
tumor samples. A clear implication of this is that the perceived
‘‘non-randomness’’ in the genomic distribution of translocation
breakpoints is not necessarily related to the initial localization of
DSBs, but could be the result of the selection process by which
only a few of those DSBs eventually survive in the cells of a tumor.
Prediction of novel fusion proteins in hematological and
solid tumors
If the two signatures identified in this work are important
determinants of breakpoint localization, then our results should be
useful for the prediction of gene fusions that have not yet been
Fusion Transcript Selection
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found in tumors. First, the information about which domain
architectures are present in the same fusion protein can be used to
select all the genes that encode a particular pair of domain
architectures. This will predict several gene fusions that are
potentially oncogenic. Information about the reading frames of the
exons belonging to those genes should identify which specific
fusions (if any) are capable of generating an in-frame fusion protein
that includes the required combination of protein domains. More
importantly, this analysis should also identify which introns are
most likely to contain the breakpoints, and thus assist in the design
of molecular strategies for the detection of those putative fusion
transcripts.
One obvious implication from our work is that many potential
gene fusions could generate the same combination of domain
architectures, because each architecture is usually encoded by
several genes. However, it is generally assumed that the majority of
chromosomal translocations responsible for the development of
human cancer have already been described [8,17]. Although some
new cases are published every year, most of them report novel
breakpoints in previously known gene fusions, or new fusions
between genes that had been previously found fused to other
partners. It is not clear why many of the potential novel gene
fusions have not been detected. A likely explanation is that the
genes involved do not meet some of the criteria that are required
for a reciprocal translocation to take place, such as proximity
within the nuclear space or co-transcription in the same nuclear
transcription factories [35–39]. Alternatively, some of these novel
gene fusions might remain undetected because they were never
searched for, since most studies focus on the detection of known
translocations. In this regard, it is interesting to consider recent
studies in which the genome of various types of cancer cells has
been interrogated in an unbiased manner [40–43]. In the case of a
diploid sample from a leukemia patient, massively parallel
sequencing uncovered novel point mutations, but no genomic
rearrangements [40]. End Sequence Profiling of cell lines from
solid tumors revealed many somatic genomic rearrangements, but
only a few of these were gene fusions. For instance, Campbell et al.
[41] used massively parallel paired-end sequencing in two lung
cancer cell lines and found 22 somatic interchromosomal
rearrangements in the NCI-H2171 cell line, but none in NCI-
H1770. Of those, only one expressed fusion transcript was
identified, although it was predicted to be out-of frame. Raphael
et al. [42] found one fusion between HYDIN gene and an
anonymous gene in MCF7 metastatic breast carcinoma cell line.
Another fusion between SCL12A2 and an expressed sequence tag
was found only in high passage MCF7 cells. In this same cell line,
in which chromosomal aberrations have been previously described
by Spectral Karyotyping (SKY) and array-Comparative Genomic
Hybridization (CGH), Hampton et al. [43] found 10 gene fusions
using end-sequence profiling with massively parallel sequencing.
Of these, only four were found to be expressed, but their
oncogenic potential was not directly tested. Considering that these
studies were performed on cell lines, the number of novel
expressed gene fusions is relatively low.
Figure 3. Requirements for the emergence of a successful fusion protein. Three exons of two hypothetical genes are shown (exons A, B and
C in blue, exons 1, 2 and 3 in orange). The initial and final reading frame of each exon is shown (+1, +2 or +3). Exons A and B of the top gene code for
a protein domain (red bar), whereas exon 3 of the bottom gene codes for another protein domain (green bar). Even if double-strand breaks (DSBs,
yellow lightning symbols) were created uniformly across the sequence of both genes, only those breakpoint combinations leading to in-frame fusion
proteins that code for both protein domains will display oncogenic potential. As a result, translocation breakpoints found in tumor samples will
cluster to specific gene regions (vertical blue arrows).
doi:10.1371/journal.pone.0004805.g003
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These recent data are also relevant to the present debate about
‘‘driver’’ and ‘‘passenger’’ mutations in cancer genomes. Due to
the inherent instability of the genomes and the clonal nature of the
tumorigenic process, many aberrations are expected to be found
when cancer genomes are interrogated in an unbiased manner, the
majority of which will be passenger aberrations with no functional
relevance to the oncogenic process. In this context, there is a great
need for new approaches that can distinguish those genomic
changes that drive tumor initiation or progression from neutral
changes that have been acquired by the clone but have no
functional impact. Our results underscore two features that could
be useful in this respect. However, due to the nature of the data
analyzed in this work, our results are particularly relevant to
hematological malignancies, which are overrepresented in our
dataset (66% of all fusions studied correspond to hematological
cancers). Chromosomal translocations have been difficult to find in
solid tumors, particularly in epithelial cancers, due to the presence
of complex karyotypes with many aberrations that are difficult to
analyze [44]. However, gene fusions with clear oncogenic potential
have been recently identified in prostate and lung cancers [45–47],
suggesting that such rearrangements might be of greater
importance for the development of solid tumors than generally
thought. It will be interesting to see whether our findings also
apply to solid malignancies, as more genomes from primary
tumors are sequenced. Even if our findings are not at present
entirely applicable to solid tumors, we believe that the two
signatures of functional selection will be evident in expressed
fusion proteins of most cancer types.
In conclusion, we identify two signatures of functional selection
in oncogenic fusion proteins: specific combinations of protein
domains and reading frame compatibility. Our results provide
experimental support for the view of cancer as an evolutionary
process at the cellular level, and highlight the importance of
selection in the recurrent emergence of clonal genetic alterations
and in the non-random distribution of translocation breakpoints in
cancer cells. We also show that building a network of protein
domain architectures that are brought together to oncogenic
fusion proteins is more informative about the mechanisms
involved than the network of gene fusions. The network of
domain architectures is less redundant, captures most of the
functional processes deregulated in oncogenesis, and will grow at a
slower rate in the future. Finally, we propose that this information
can be used to assess the functional relevance of novel
chromosomal translocations and to predict the position of
breakpoints in the genes involved.
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